Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PatientsLikeMe Developing Platform To Validate Patient-Reported Outcomes

Executive Summary

While the primary objective will be to help members of the online patient community better manage their health, the new platform will offer an opportunity for pharmaceutical companies to validate patient-reported outcomes that they develop, something that could be useful as PROs gain more traction in the FDA review process.

You may also be interested in...



Genentech Social Media Collaboration Will Focus On Patient Experiences In Cancer

Under the five-year research collaboration, Genentech will have broad access to the online patient network PatientsLikeMe, which has 250,000 members.

Linking E-Health Records With Claims Offers Context On Outcomes – Optum Labs Exec

Despite the promise electronic health records hold for comparative effectiveness research, clinical information needs to be lined up with claims data to get a more complete picture, Optum Labs’ William Crown said during the recent Comparative Effectiveness Summit.

People In The News: Government Officials Go Private; New Top Leadership At Advaxis, Aerie

Former FDA CIO Perakslis joins IT consultancy; Former DoJ FCA litigator May joins Arnold & Porter; PatientsLikeMe names researchers to pilot test new PRO validation tool; more personnel announcements in this month’s column.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel